These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20680481)

  • 21. A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum.
    Narendran R; Mason NS; Laymon CM; Lopresti BJ; Velasquez ND; May MA; Kendro S; Martinez D; Mathis CA; Frankle WG
    J Pharmacol Exp Ther; 2010 May; 333(2):533-9. PubMed ID: 20103586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals.
    Seeman P
    Synapse; 2009 Mar; 63(3):186-92. PubMed ID: 19086090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.
    Nakajima S; Caravaggio F; Boileau I; Chung JK; Plitman E; Gerretsen P; Wilson AA; Houle S; Mamo DC; Graff-Guerrero A
    J Cereb Blood Flow Metab; 2015 Nov; 35(11):1812-8. PubMed ID: 26058690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [
    Schneier FR; Slifstein M; Whitton AE; Pizzagalli DA; Reinen J; McGrath PJ; Iosifescu DV; Abi-Dargham A
    Biol Psychiatry; 2018 Oct; 84(8):563-573. PubMed ID: 30041971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.
    Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M
    Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.
    Narendran R; Frankle WG; Mason NS; Laymon CM; Lopresti BJ; Price JC; Kendro S; Vora S; Litschge M; Mountz JM; Mathis CA
    Synapse; 2009 Jul; 63(7):574-84. PubMed ID: 19301416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.
    Caravaggio F; Kegeles LS; Wilson AA; Remington G; Borlido C; Mamo DC; Graff-Guerrero A
    Synapse; 2016 Nov; 70(11):453-60. PubMed ID: 27341789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.
    Gallezot JD; Zheng MQ; Lim K; Lin SF; Labaree D; Matuskey D; Huang Y; Ding YS; Carson RE; Malison RT
    J Nucl Med; 2014 Jun; 55(6):960-6. PubMed ID: 24732151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D
    Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automated preparation of the dopamine D2/3 receptor agonist ligand [11C]-(+)-PHNO for human PET imaging studies.
    Plisson C; Huiban M; Pampols-Maso S; Singleton G; Hill SP; Passchier J
    Appl Radiat Isot; 2012 Feb; 70(2):380-7. PubMed ID: 22055845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET Imaging of Pancreatic Dopamine D
    Bini J; Sanchez-Rangel E; Gallezot JD; Naganawa M; Nabulsi N; Lim K; Najafzadeh S; Shirali A; Ropchan J; Matuskey D; Huang Y; Herold KC; Harris PE; Sherwin RS; Carson RE; Cline GW
    J Nucl Med; 2020 Apr; 61(4):570-576. PubMed ID: 31601695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
    McCormick PN; Wilson VS; Wilson AA; Remington GJ
    Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum.
    Drevets WC; Price JC; Kupfer DJ; Kinahan PE; Lopresti B; Holt D; Mathis C
    Neuropsychopharmacology; 1999 Dec; 21(6):694-709. PubMed ID: 10633475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.
    Narendran R; Mason NS; Chen CM; Himes M; Keating P; May MA; Rabiner EA; Laruelle M; Mathis CA; Frankle WG
    Synapse; 2011 Oct; 65(10):991-7. PubMed ID: 21360596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.
    Egerton A; Ahmad R; Hirani E; Grasby PM
    Psychopharmacology (Berl); 2008 Nov; 200(4):487-96. PubMed ID: 18597077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between subcortical brain volume and striatal dopamine D
    Caravaggio F; Ku Chung J; Plitman E; Boileau I; Gerretsen P; Kim J; Iwata Y; Patel R; Chakravarty MM; Remington G; Graff-Guerrero A
    Hum Brain Mapp; 2017 Nov; 38(11):5519-5534. PubMed ID: 28752565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.
    Frankle WG; Paris J; Himes M; Mason NS; Mathis CA; Narendran R
    Biol Psychiatry; 2018 Apr; 83(8):707-714. PubMed ID: 29325847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.